How many drugs treat Pulmonary embolism?

Drug Landscape tracks 10 marketed treatments for Pulmonary embolism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-embolism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pulmonary embolism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary embolism (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary embolism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Dabigatran Etexilate	DABIGATRAN	Boehringer Ingelheim			2025-01-01
Savaysa	edoxaban	Daiichi Sankyo Inc	Factor Xa Inhibitor	Coagulation factor X	2015-01-01
Xarelto	rivaroxaban	Johnson & Johnson	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Pradaxa	dabigatran-etexilate	Boehringer Ingelheim	Direct thrombin inhibitor	Thrombin (serine protease)	2010-01-01
Activase	ALTEPLASE	Roche		Plasminogen	1996-01-01
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Enoxaparin	Enoxaparin	Dana-Farber Cancer Institute		Antithrombin-III
Xarelto	Xarelto	University Hospital, Montpellier		Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X
Lovenox	Lovenox	University of Monastir		Antithrombin-III

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 2 drugs in Pulmonary embolism
Daiichi Sankyo Inc · 1 drug in Pulmonary embolism
Dana-Farber Cancer Institute · 1 drug in Pulmonary embolism
Generic (originally Boehringer Ingelheim) · 1 drug in Pulmonary embolism
Johnson & Johnson · 1 drug in Pulmonary embolism
Medical College of Wisconsin · 1 drug in Pulmonary embolism
Pfizer · 1 drug in Pulmonary embolism
Pfizer Inc. · 1 drug in Pulmonary embolism
Roche · 1 drug in Pulmonary embolism
Sanofi · 1 drug in Pulmonary embolism
University Hospital, Montpellier · 1 drug in Pulmonary embolism
· 1 drug in Pulmonary embolism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary embolism:

Cite this brief

Drug Landscape (2026). Pulmonary embolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-embolism. Accessed 2026-06-10.

Pulmonary embolism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing